Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study (Q38245038)
Jump to navigation
Jump to search
scientific article published on 27 August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study |
scientific article published on 27 August 2014 |
Statements
1 reference
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study (English)
1 reference
Takashi Seto
1 reference
Terufumi Kato
1 reference
Makoto Nishio
1 reference
Koichi Goto
1 reference
Shinji Atagi
1 reference
Yukio Hosomi
1 reference
Noboru Yamamoto
1 reference
Toyoaki Hida
1 reference
Makoto Maemondo
1 reference
Kazuhiko Nakagawa
1 reference
Seisuke Nagase
1 reference
Isamu Okamoto
1 reference
Takeharu Yamanaka
1 reference
Kosei Tajima
1 reference
Ryosuke Harada
1 reference
Masahiro Fukuoka
1 reference
Nobuyuki Yamamoto
1 reference
27 August 2014
1 reference
1 reference
Identifiers
1 reference